C-Rad AB (LTS:0R44) Other Current Receivables: kr63.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R44 C-Rad AB LTS:0R44
82 GF Score
Price kr37.90
GF Value kr33.99
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is C-Rad AB Other Current Receivables?

C-Rad AB LTS:0R44 +3.84% 82 Other Current Receivables is kr63.1 Mil as of Jun. 2026. GuruFocus rates LTS:0R44 with a GF Score™ of 82/100 and a GF Value™ of kr33.99 (Modestly Overvalued). The stock has 4 warning signs investors should review.

C-Rad AB's Other Current Receivables for the quarter that ended in Jun. 2026 was kr63.1 Mil.

C-Rad AB's quarterly Other Current Receivables increased from Dec. 2025 (kr55.51 Mil) to Mar. 2026 (kr61.50 Mil) and increased from Mar. 2026 (kr61.50 Mil) to Jun. 2026 (kr63.10 Mil).

C-Rad AB's annual Other Current Receivables increased from Dec. 2023 (kr47.90 Mil) to Dec. 2024 (kr62.52 Mil) but then declined from Dec. 2024 (kr62.52 Mil) to Dec. 2025 (kr55.51 Mil).

C-Rad AB Other Current Receivables Related Terms

C-Rad AB Other Current Receivables Historical Data

* Premium members only.

The historical data trend for C-Rad AB's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

C-Rad AB Other Current Receivables Chart

C-Rad AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.79 33.18 47.90 62.52 55.51

C-Rad AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.80 49.80 55.51 61.50 63.10
LTS:0R44
82GF Score
C-Rad AB LTS:0R44
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

C-Rad AB Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of kr63.1 Mil mean?
C-Rad AB (LTS:0R44) has a Other Current Receivables of kr63.1 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on C-Rad AB and its competitors.
Is C-Rad AB's Other Current Receivables too high?
C-Rad AB's current Other Current Receivables is kr63.1 Mil. Overall, C-Rad AB has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Other Current Receivables compare to ABT and SYK?
C-Rad AB's Other Current Receivables of kr63.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on C-Rad AB and its competitors. C-Rad AB's current Other Current Receivables is kr63.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Modestly Overvalued. The stock's GF Value™ is kr33.99, compared to a current price of kr37.90 — trading 11.5% above its estimated fair value. The current Other Current Receivables is kr63.1 Mil. C-Rad AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current Other Current Receivables is kr63.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is C-Rad AB (LTS:0R44) Overvalued in 2026?

Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued. The current stock price of kr37.90 is trading 11.5% above its estimated GF Value™ of kr33.99. GuruFocus considers C-Rad AB to be Modestly Overvalued.

Key valuation signals for LTS:0R44:

  • Other Current Receivables: kr63.1 Mil
  • GF Value™: kr33.99 vs. price of kr37.90 (11.5% above fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

C-Rad AB Business Description

Other Exchanges CRAD B:Sweden24C:Germany
Address Sjukhusvagen 12K, Uppsala, SWE, 753 09
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
82GF Score

Get the complete analysis for LTS:0R44

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr37.90
Price
kr33.99
GF Value